Earnings Releases·Nov 4, 2026, 4:03 PM ET

STAAR Surgical — Third Quarter 2026 Earnings Summary

Net sales declined 12% year-over-year to $83.4 million, though excluding $25.9 million of previously deferred China sales, sales grew 21%; net income fell to $5.6 million ($0.11/share) from $8.9 million ($0.18/share) in the prior-year quarter, with adjusted EBITDA dropping to $14.4 million ($0.28/share) from $34.7 million ($0.69/share).
Management raised full-year ambitions, expressing confidence in delivering strong GAAP net income and free cash flow, while noting that temporary gross margin pressures are expected to abate in Q4 2026 as tariffs and inventory provisions ease.
The Board authorized a $50 million share repurchase program in September, reflecting confidence in the business and a belief that shares are undervalued, while the company maintains a debt-free balance sheet with $206.4 million in cash and investments.
Strategic progress includes the completion of manufacturing transition for the Chinese market to a Swiss facility to reduce tariff exposure, the initiation of clinical trials for next-generation presbyopia technologies, and recent regulatory label expansions adding approximately 34 million new patients in the U.S. and Brazil.